A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
Matti Aapro(Clinique de Genolier), H. S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Antônio Rossi(Helsinn (Switzerland)), Giada Rizzi(Helsinn (Switzerland)), Maria Elisa Borroni(Helsinn (Switzerland)), Igor Bondarenko(Dnipropetrovsk State Medical Academy), Tomasz Sarosiek(NZOZ Centrum Alergologii), Cristina Oprean, Servando Cardona‐Huerta(Universidad Autónoma de Nuevo León), Vito Lorusso(Istituto Tumori Bari), M. Karthaus, Lee S. Schwartzberg(Campbell Clinic), Steven M. Grunberg(Allen Hospital)
Cited by 247Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis